Fonti utilizzate nella revisione corrente
AIRTUM Working Group. I tumori in Italia Rapporto 2019. Sopravvivenza. Epidemiol Prev 2018; 41(2):Suppl. 1. 3.
Associazione Italiana di Oncologia Medica (AIOM). Tumori dell’ovaio, edizione 2020. Associazione Italiana di Oncologia Medica: Milano, Italy; 2020. Available from https://www.aiom.it/linee-guida-aiom/. (Ultimo accesso 18 Maggio 2021).
Associazione Italiana di Oncologia Medica (AIOM). Tumori dell’utero, edizione 2020. Associazione Italiana di Oncologia Medica: Milano, Italy; 2020. Available from https://www.aiom.it/linee-guida-aiom/. (Ultimo accesso 18 Maggio 2021).
Colombo N, Creutzberg C, Amant F, et al.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016 Jan;27(1):16-41. doi: 10.1093/annonc/mdv484
Colombo N, Sessa C, duBois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. AnnOncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062.
Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. Obstet Gynecol. 2017 Sep;130(3):e146-e149. doi: 10.1097/AOG.0000000000002299.
Dodge J, Covens A, Lacchetti C, Elit L, et al. Management of a Suspicious Adnexal Mass. Program in Evidence-based Care Evidence-Based Series No.: 4-15 Version 2. Cancer Care Ontario: Toronto ON, Canada; 2016, September. Available from https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/466.(Ultimo accesso 18 Maggio 2021).
Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014 Mar;29(3):400-12. doi: 10.1093/humrep/det457.
Gion M, Trevisiol C, Rainato G, Fabricio ASC: Marcatori Circolanti in Oncologia. Guida all'Uso Clinico Appropriato. I Quaderni di Monitor AGENAS. Agenzia Nazionale per i Servizi Sanitari Regionali: Rome, Italy;2016. Available from https://www.agenas.gov.it/i-quaderni-di-monitor-%E2%80%93-supplementi-alla-rivista/936-marcatori-circolanti-oncologia-guida-uso-clinico-appropriato. (Ultimo accesso 18 Maggio 2021).
Gruppo di Lavoro AIOM - SIGU - SIBIOC - SIAPEC-IAP. Raccomandazioni per l’implementazione del test BRCA nelle pazienti con carcinoma ovarico e nei familiari a rischio elevato di neoplasia. v2 -gennaio 2019. Available from /https://www.aiom.it/raccomandazioni-aiom-per-limplementazione-dell’analisi-mutazionale-brca-nei-pazienti-con-carcinoma-della-prostata-metastatico. (ultimo accesso 18 Maggio 2021).
Lancaster JM, Powell CB, Chen LM, Richardson DL; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. GynecolOncol. 2015 Jan;136(1):3-7. doi: 10.1016/j.ygyno.2014.09.009.
National Collaborating Centre for Cancer (UK). Ovarian Cancer: The Recognition and Initial Management of Ovarian Cancer. Cardiff (UK): National Collaborating Centre for Cancer (UK); 2011 Apr. Available from https://www.nice.org.uk/Guidance/CG122. (Ultimo accesso 18 Maggio 2021).
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic Version 2.2021. National Comprehensive Cancer Network: Fort Washington, PA, USA; 2020. Available from https://www.nccn.org/professionals/physician_gls/default.aspx. (ultimo accesso 18 Maggio 2021).
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 2.2018. National Comprehensive Cancer Network: Fort Washington, PA, USA; 2020. Available from https://www.nccn.org/professionals/physician_gls/default.aspx. (ultimo accesso 18 Maggio 2021).
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Uterine Neoplasms, Version 1.2021. National Comprehensive Cancer Network: Fort Washington, PA, USA; 2020. Available from https://www.nccn.org/professionals/physician_gls/default.aspx. (ultimo accesso 18 Maggio 2021).
National Collaborating Centre for Cancer (UK). Ovarian Cancer: The Recognition and Initial Management of Ovarian Cancer. Cardiff (UK): National Collaborating Centre for Cancer (UK); 2011 Apr. Available from https://www.nice.org.uk/Guidance/CG122. (Ultimo accesso 18 Maggio 2021).
Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. AnnOncol. 2016 Sep;27(suppl 5):v103-v110. doi: 10.1093/annonc/mdw327.
Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol. 2015 Apr;125(4):1006-1026. doi: 10.1097/01.AOG.0000462977.61229.de.
Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet Gynecol. 2017 Sep;130(3):e110-e126. doi: 10.1097/AOG.0000000000002296.
Scottish Intercollegiate Guidelines Network (SIGN). Management of Epithelial Ovarian Cancer: A National Clinical Guideline (SIGN publication no. 135). SIGN: Edinburgh, UK; 2018. Available from http://www.sign.ac.uk. (ultimo accesso 18 Maggio 2021).
Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586.
US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Feb 13;319(6):588-594. doi: 10.1001/jama.2017.21926
Fonti utilizzate nelle precedenti revisioni
Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.
Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 219-220.
Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 210-211.
Mason, J. (Updated 2008 June 10). CA-125. MedlinePlus Medical Encyclopedia. [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007217.htm. Accessed March 2009.
(2007 March). Ovarian Cancer Resource Guide for women with recurrent disease. NOCC, Inc. [On-line information]. PDF available for download at http://www.ovarian.org/Images/ResourceGuideRecurrentOvarianCancer.pdf. Accessed March 2009.
(2008 August 26). Ovarian Cancer: Why Screening Isn't Routine. American Cancer Society. [On-line information]. Available online at http://www.cancer.org/docroot/SPC/content/SPC_1_ovarian_Q_A_Saslow.asp. Accessed March 2009.
(Modified 2008 April 3). Ovarian Cancer Screening (PDQ®), Health Professional Version. NCI, U.S. National Institutes of Health. [On-line information]. Available online at http://www.cancer.gov/cancertopics/pdq/screening/ovarian/healthprofessional. Accessed March 2009.
(2008 July). Understanding CA 125 Levels: A Guide for Ovarian Cancer Patients. Gynecologic Cancer Foundation. [On-line information]. PDF available for download at http://www.thegcf.org/wcnlib/downloads/CA125levels_July2008.pdf. Accessed March 2009.
(Updated 2012 August 1). Fazal Hussain, F. and Homoud, H. Gynecologic Tumor Markers Tumor Marker Overview. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/269839-overview. Accessed October 2012.
Zieve, D. and Chen Y. (Updated 2011 December 15). CA-125. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007217.htm. Accessed October 2012.
(Revised 2012 October 5). Can ovarian cancer be found early? American Cancer Society [On-line information]. Available online at http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-detection. Accessed October 2012.
Grenache, D. et. al. (Updated 2012 May). Ovarian Cancer. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/OvarianCancer.html?client_ID=LTD. Accessed October 2012.
Schmidt, C. (2011 December 05). CA-125: A Biomarker Put to the Test. Medscape Today News from J Natl Cancer Inst. V 103(17):1290-1281 [On-line information]. Available online at http://www.medscape.com/viewarticle/750770. Accessed October 2012.
Rustin, G. et. al. (2012 March 08). CA-125: To Monitor or Not to Monitor? For Ovarian Cancer Patients in Remission. Medscape Today News [On-line information]. Available online at http://www.medscape.com/viewarticle/759809. Accessed October 2012.
(2012 September). Screening for Ovarian Cancer, U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. USPSTF [On-line information]. Available online at http://www.uspreventiveservicestaskforce.org/uspstf12/ovarian/ovarcancerrs.htm. Accessed November 2012.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 210-211.
Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 499-500.
2016 review by Carolyn Sue Ziegler, MBA, MLS(CM).
Pagana, Kathleen D, Pagana, Timothy J, and Pagana, Theresa N. (©2015) Mosby’s Diagnostic & Laboratory Test Reference 12th Edition: Mosby, Inc. Saint Louis, MO. Pp.199-200.
(Updated Oct. 30, 2015) Gentry George T King, M.D. CA 125: Reference Range, Interpretation, Collection and Panels. Available online at http://emedicine.medscape.com/article/2087557-overview. Accessed 23/2016.
Ovarian Cancer National Alliance. Risk Factors. Available online at http://www.ovariancancer.org/about/risk-factors. Accessed 2/8/2016.
Ovarian Cancer National Alliance. Symptoms and Detection of Ovarian Cancer. Available online at http://www.ovariancancer.org/about/symptoms-of-ovarian-cancer-detection. Accessed 2/8/2016.
(Updated 13 January 2016) CA-125 blood test. MedlinePlus Medical Encyclopedia. Available online at https://www.nlm.nih.gov/medlineplus/ency/article/007217.htm. Accessed 2/3/2016.
(©2016) Mayo Clinic Mayo Medical Laboratories. Human Epididymis Protein 4, Serum. Available online at http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/62137. Accessed 2/10/2016.
Ovarian Cancer Testing: HE4 Ovarian Cancer Monitoring. Quest Diagnostics. Available online at http://www.questdiagnostics.com/home/patients/tests-a-z/ovarian-cancer/he4-monitoring.html. Accessed Feb 2016.
(©2014) Laboratory Corporation of America. A Technical Review, Human Epididymis Protein 4 (HE4), Monitoring Patients With Epithelial Ovarian Carcinoma.
(Jan 14, 2015) Fazal Hussain. Gynecologic Tumor Markers, Cancer Antigen 125. Medscape Review. Available online at http://emedicine.medscape.com/article/269839-overview#a2. Accessed 2/8/2016.
(Aug 5, 2014) American Cancer Society. Ovarian Cancer: Detailed Guide. Available online at http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-what-is-ovarian-cancer. Accessed 2/8/2016.